1De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5 fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol, 1988, 24: 1499- 1503.
2QUASAR Collaborative Group.Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as an adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet, 2000, 356:1276.
3Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin ) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer, 2006, 94 : 969-975.
4Macdonald JS. Adjuvant therapy of colon cancer. Ca Cancer J Clin, 1999, 49:202-219.
5Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J, 2003, 33:119-124.
6Saris CP, Van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis, 1996, 17:2763-2769.
7Cassidy J, Tabemero J, Twelves C, et al. XELOX ( capecitabine plus oxaliplatin ): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004, 22:2084-2091.
8Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase Ⅲ trail conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 2001,37:597-604.
